SCHEDULE: Carlyle Group Discloses 20.6% Stake in Medline Inc.

The Carlyle Group and its affiliates have filed a Schedule 13G reporting a 20.6% beneficial ownership stake in Medline Inc. Class A Common Stock.

Summary

• The Carlyle Group Inc. and various affiliated entities reported a collective beneficial ownership of 187,083,713 shares of Medline Inc. Class A Common Stock.
• This ownership represents 20.6% of the total outstanding Class A Common Stock as of April 13, 2026.
• The filing reflects the aggregation of holdings across multiple investment vehicles, including various 'Holdco' limited partnerships.
• The reported shares include both direct holdings and shares underlying Common Units of Medline Holdings, LP, which are convertible on a one-to-one basis.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing ownership levels without indicating immediate changes in strategy or intent.

Positives

• Significant institutional backing from a major private equity firm, indicating long-term confidence in the issuer.
• Clear and transparent disclosure of complex ownership structures across multiple investment vehicles.

Negatives

• High concentration of ownership by a single private equity group may influence corporate governance and strategic direction.

Risks

• Potential for future divestment or secondary offerings by the Carlyle Group, which could exert downward pressure on the share price.
• Concentration of voting power among a small group of affiliated entities.

Future Outlook

The filing does not provide specific forward-looking guidance regarding the issuer's operations, but confirms the reporting persons' ongoing investment position.

Industry Context

StockSavvy.ai notes that large-scale 13G filings by private equity firms like Carlyle are standard in the post-IPO lifecycle, often signaling a transition from private ownership to public market liquidity.

Comparison to Industry Standards

• The 20.6% stake is consistent with typical 'exit' or 'monetization' strategies employed by private equity firms following a portfolio company's public listing.
• The structure of the filing is standard for complex multi-entity investment groups under SEC Rule 13d-1.

Stakeholder Impact

• Shareholders should be aware of the significant influence held by the Carlyle Group due to their 20.6% stake.

Next Steps

• Continued monitoring of future 13G/13D filings for any changes in the Carlyle Group's ownership percentage.

Key Dates

Keywords

Medline, Carlyle Group, Schedule 13G, Beneficial Ownership, Private Equity, Institutional Investor